<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, there is promise in the use of hyperimmune serum as passive treatment of desperately ill patients. Very limited experience, anecdotal at best, suggests that antibodies can mitigate infection in these patients 
 <xref rid="onco13337-bib-0011" ref-type="ref">11</xref>. Companies are investigating the development of antiviral monoclonal antibodies for this purpose, and convalescent sera are also being tested.
</p>
